Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human SAR439459 monotherapy and combination with cemiplimab in advanced solid tumors
NL-OMON55468Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SAR439459 and cemiplimab in Nonhematologic neoplasms, melanoma, colorectal adenocarcinoma and 3 more, sponsored by Sanofi. Primary endpoints: Incidence of dose-limiting toxicities and Objective response rate. Started Nov 2019; status: completed.
02
Drugs
SAR439459cemiplimab
03
Conditions
Nonhematologic neoplasmsmelanomacolorectal adenocarcinomatransitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55468.